Results 91 to 100 of about 72,405 (280)
Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis
The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients.
core
Abstract Objectives Pediatric autoimmune hepatitis (pAIH) is an acute or chronic inflammatory liver disease, caused by a dysregulation of the immune system. Autoimmune sclerosing cholangitis (ASC) additionally affects the bile ducts. Traditional first‐line treatment (FLT) consists of prednisolone and azathioprine.
Marie Korell +10 more
wiley +1 more source
Background/AimsIn patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission.
doaj +1 more source
Background: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared.
Abhinav Vasudevan +4 more
doaj +1 more source
Infliximab-Induced Optic Perineuritis and Facial Myositis
Optic neuritis is an inflammatory condition involving the optic nerve with autoimmune, demyelinating, toxic or infectious etiologies. Myositis is a rare but reported complication of infliximab (1), whereas the incidence of infliximab-induced optic ...
Loulwah Mukharesh; Amanda Tinsley
core
Effectiveness and Safety of Infliximab in Two Cases of Severe Chondrocalcinosis: Nine Years of Follow-Up [PDF]
Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD). Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described ...
Bruno F. Bettencourt +13 more
core +2 more sources
Abstract Objectives Outcomes of anti‐tumor necrosis factor (anti‐TNF) discontinuation in pediatric patients with inflammatory bowel disease (IBD) remain unclear. We aimed to quantify relapse and biologic re‐initiation rates following anti‐TNF withdrawal in patients in sustained clinical remission for at least 6 months. Methods Patients' characteristics
Maya Granot +24 more
wiley +1 more source
Objective: We report the incidence and treatment of infusion reactions to infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor a, in a large cohort of patients with rheumatoid arthritis.
S. Todesco, P. Ostuni, C. Botsios
doaj +1 more source
Profile of infliximab in the treatment of pediatric Crohn’s disease
Jaroslaw Kierkus,1 Edyta Szymanska,2 Grzegorz Oracz,1 Anna Wiernicka,1 Maciej Dadalski1 1Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, 2Department of Pediatrics, Nutrition and Metabolic Disorders, The Children’s ...
Szymanska E +4 more
core
Obesity in paediatric inflammatory bowel disease: The emerging double burden—A narrative review
Abstract Obesity is increasingly recognised in paediatric inflammatory bowel disease (IBD), challenging the traditional view of paediatric IBD as a condition primarily associated with undernutrition, impaired growth, and delayed puberty. In parallel with the global rise in childhood obesity, overweight and obesity are now increasingly reported in ...
Martina Di Benedetto +5 more
wiley +1 more source

